Business Context and Reporting Period
Company: Establishment Labs Holdings Inc.
Filing Type: Form 8-K (Current Report)
Date: January 11, 2023
Context: The filing discloses presentation materials for the annual J.P. Morgan Healthcare Conference scheduled for January 12, 2023. The Company is a British Virgin Islands entity with principal executive offices in Costa Rica, trading on the NASDAQ Capital Market under the symbol "ESTA".
Key Financial Metrics
This Form 8-K does not contain audited financial statements, revenue figures, profit data, cash flow, margins, debt levels, or liquidity metrics for any reporting period. The document explicitly states that the information provided is not a substitute for full interim or annual financial statements prepared in accordance with U.S. GAAP.
Material Changes and Operational Updates
- Regulatory Status: The Company notified the U.S. Food and Drug Administration (FDA) prior to the end of 2022 that it was ready to submit Module 4 of the pre-market approval (PMA) for Motiva Implants.
- Submission Timeline: The Company expects to file Module 4 during the first quarter of 2023 to enable efficient review of the full submission.
Guidance, Outlook, and Risks
- Revenue Guidance: Management expects to achieve $500 million in annual revenue in fiscal year 2026.
- Forward-Looking Statements: The report contains forward-looking statements regarding FDA timing and future revenue. These are subject to risks and uncertainties and should not be viewed as guarantees.
- Disclaimer: The Company is not undertaking to update the presentation materials. The data has not been audited or reviewed by Marcum LLP, the independent registered public accounting firm.
Investor Verification Checklist
- Verify the actual submission date of Module 4 of the PMA to the FDA in Q1 2023.
- Review the full presentation materials (Exhibit 99.1) for detailed assumptions behind the $500 million 2026 revenue target.
- Monitor subsequent filings for any updates on the FDA review timeline or potential delays.
- Confirm the Company's most recent audited financial statements (10-K or 10-Q) for current liquidity and debt positions, as this 8-K does not provide them.